Investigating genetic links to asthma severity in Chinese patients
Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.
Chinese University of Hong Kong · NCT06196034
This study is trying to see if certain genes are linked to how severe asthma is in Chinese patients, especially those with moderate to severe symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Locations | 2 sites (Hong Kong, New Territories and 1 other locations) |
| Trial ID | NCT06196034 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the genetic associations with varying severities of asthma among the Chinese population. It focuses on identifying specific genetic polymorphisms that may contribute to asthma susceptibility and severity, particularly in patients with moderate to severe asthma. The study will compare the frequency and distribution of these genetic variants in asthma patients against healthy controls, while also considering environmental factors that may influence asthma development. By addressing the underrepresentation of non-European populations in asthma genetics research, this study seeks to provide valuable insights into the genetic basis of asthma in Chinese individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese patients with a confirmed diagnosis of asthma who can provide informed consent.
Not a fit: Patients experiencing acute asthma exacerbations or those with respiratory diseases that mimic asthma symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of asthma genetics, potentially informing personalized treatment strategies for patients.
How similar studies have performed: While there have been studies on asthma genetics, this research is particularly novel as it focuses on the Chinese population, which has been underrepresented in existing literature.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 * Able to sign written informed consent form to participate in the study. Exclusion Criteria: * • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) * Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. * Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma.
Where this trial is running
Hong Kong, New Territories and 1 other locations
- The Chinese University of Hong Kong — Hong Kong, New Territories, Hong Kong (RECRUITING)
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Study coordinator: David SC Hui, MD
- Email: dschui@cuhk.edu.hk
- Phone: 35053133
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Asthma